AR064031A1 - Compuestos de azaindolilo y metodos de uso - Google Patents
Compuestos de azaindolilo y metodos de usoInfo
- Publication number
- AR064031A1 AR064031A1 ARP070105307A ARP070105307A AR064031A1 AR 064031 A1 AR064031 A1 AR 064031A1 AR P070105307 A ARP070105307 A AR P070105307A AR P070105307 A ARP070105307 A AR P070105307A AR 064031 A1 AR064031 A1 AR 064031A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cr19r20
- nhc
- cr14r15
- noc
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 147
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 125000003118 aryl group Chemical group 0.000 abstract 10
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 8
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 8
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 8
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000037273 Pathologic Processes Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 230000002547 anomalous effect Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000009054 pathological process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86805506P | 2006-11-30 | 2006-11-30 | |
| US91762007P | 2007-05-11 | 2007-05-11 | |
| US94474307P | 2007-06-18 | 2007-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064031A1 true AR064031A1 (es) | 2009-03-04 |
Family
ID=39169665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105307A AR064031A1 (es) | 2006-11-30 | 2007-11-29 | Compuestos de azaindolilo y metodos de uso |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7855216B2 (OSRAM) |
| EP (1) | EP2099796B1 (OSRAM) |
| JP (1) | JP5211063B2 (OSRAM) |
| AR (1) | AR064031A1 (OSRAM) |
| AT (1) | ATE511509T1 (OSRAM) |
| AU (1) | AU2007325123B2 (OSRAM) |
| CA (1) | CA2672327A1 (OSRAM) |
| CL (1) | CL2007003444A1 (OSRAM) |
| DK (1) | DK2099796T3 (OSRAM) |
| PE (1) | PE20081354A1 (OSRAM) |
| PL (1) | PL2099796T3 (OSRAM) |
| PT (1) | PT2099796E (OSRAM) |
| TW (1) | TW200829586A (OSRAM) |
| WO (1) | WO2008067481A1 (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011526267A (ja) * | 2008-07-03 | 2011-10-06 | バイエル ファーマ アクチエンゲゼルシャフト | 化合物および放射性医薬品の製造方法 |
| WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
| CA2789696C (en) | 2010-02-25 | 2017-11-07 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| CN103038364A (zh) | 2010-03-09 | 2013-04-10 | 达纳－法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
| SG10201505951VA (en) * | 2010-07-30 | 2015-08-28 | Oncotherapy Science Inc | Quinoline derivatives and melk inhibitors containing the same |
| WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| UY34893A (es) | 2012-07-10 | 2014-02-28 | Takeda Pharmaceutical | Derivados de azaindol |
| EP2916859B1 (en) | 2012-11-02 | 2017-06-28 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| UA111925C2 (uk) | 2012-12-11 | 2016-06-24 | Федора Фармасьютікалз Інк. | БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| WO2015196072A2 (en) | 2014-06-19 | 2015-12-23 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| WO2017180581A1 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| US11161845B2 (en) | 2017-05-19 | 2021-11-02 | Nflection Therapeutics, Inc. | Pyrrolopyridine-aniline compounds for treatment of dermal disorders |
| ES2913213T3 (es) | 2017-05-19 | 2022-06-01 | Nflection Therapeutics Inc | Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos |
| KR102811888B1 (ko) | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| US20210008047A1 (en) | 2018-02-13 | 2021-01-14 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| WO2020106305A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Thienyl-aniline compounds for treatment of dermal disorders |
| CA3120337A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Naphthyridinone-aniline compounds for treatment of dermal disorders |
| EP3883552B1 (en) | 2018-11-20 | 2025-04-09 | NFlection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| MX2024006058A (es) | 2021-11-23 | 2024-07-10 | Nflection Therapeutics Inc | Formulaciones de compuestos de pirrolopiridina-anilina. |
| EP4469456A4 (en) * | 2022-01-28 | 2025-12-31 | Insilico Medicine Ip Ltd | Ectunocleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) inhibitors and their uses |
| CN119013276A (zh) * | 2022-03-04 | 2024-11-22 | 三进制药株式会社 | 新型杂环化合物和包含该化合物的药物组合物 |
| WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
| WO2025026383A1 (en) * | 2023-08-02 | 2025-02-06 | Insilico Medicine Ip Limited | Crytsalline forms of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof |
| WO2025100940A1 (ko) * | 2023-11-07 | 2025-05-15 | 보로노이 주식회사 | 헤테로아릴 유도체 화합물 및 이의 용도 |
| WO2026019990A1 (en) | 2024-07-18 | 2026-01-22 | Genentech, Inc. | Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| ATE361910T1 (de) | 2002-04-23 | 2007-06-15 | Aventis Pharma Inc | 3-(pyridinyl-amino)-1h-indol-2-carbonsäure- verbindungen als inhibitoren der interleukin-4 genexpression |
| US6929411B2 (en) * | 2003-09-03 | 2005-08-16 | Hewlett-Packard Development Company, L.P. | Selectable control of raster image processor |
| GB0412914D0 (en) * | 2004-06-10 | 2004-07-14 | Oxagen Ltd | Compounds |
| PE20060526A1 (es) * | 2004-06-15 | 2006-07-13 | Schering Corp | Compuestos triciclicos como antagonistas de mglur1 |
| US7598259B2 (en) * | 2004-06-15 | 2009-10-06 | Schering Corporation | mGluR1 antagonists as therapeutic agents |
| DE102005013621A1 (de) * | 2005-03-24 | 2006-09-28 | Curacyte Discovery Gmbh | Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika |
| AR070127A1 (es) * | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
-
2007
- 2007-11-29 CL CL200703444A patent/CL2007003444A1/es unknown
- 2007-11-29 PE PE2007001679A patent/PE20081354A1/es not_active Application Discontinuation
- 2007-11-29 AR ARP070105307A patent/AR064031A1/es unknown
- 2007-11-29 PT PT07854844T patent/PT2099796E/pt unknown
- 2007-11-29 TW TW096145474A patent/TW200829586A/zh unknown
- 2007-11-29 AU AU2007325123A patent/AU2007325123B2/en not_active Ceased
- 2007-11-29 DK DK07854844.3T patent/DK2099796T3/da active
- 2007-11-29 WO PCT/US2007/085962 patent/WO2008067481A1/en not_active Ceased
- 2007-11-29 PL PL07854844T patent/PL2099796T3/pl unknown
- 2007-11-29 JP JP2009539490A patent/JP5211063B2/ja not_active Expired - Fee Related
- 2007-11-29 US US11/947,656 patent/US7855216B2/en not_active Expired - Fee Related
- 2007-11-29 AT AT07854844T patent/ATE511509T1/de active
- 2007-11-29 CA CA002672327A patent/CA2672327A1/en not_active Abandoned
- 2007-11-29 EP EP07854844A patent/EP2099796B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT2099796E (pt) | 2011-09-06 |
| EP2099796A1 (en) | 2009-09-16 |
| CA2672327A1 (en) | 2008-06-05 |
| EP2099796B1 (en) | 2011-06-01 |
| DK2099796T3 (da) | 2011-09-05 |
| AU2007325123B2 (en) | 2012-12-13 |
| ATE511509T1 (de) | 2011-06-15 |
| WO2008067481A1 (en) | 2008-06-05 |
| TW200829586A (en) | 2008-07-16 |
| PE20081354A1 (es) | 2008-11-14 |
| CL2007003444A1 (es) | 2008-06-27 |
| US7855216B2 (en) | 2010-12-21 |
| PL2099796T3 (pl) | 2011-10-31 |
| HK1135099A1 (en) | 2010-05-28 |
| JP5211063B2 (ja) | 2013-06-12 |
| JP2010511626A (ja) | 2010-04-15 |
| US20080242655A1 (en) | 2008-10-02 |
| AU2007325123A1 (en) | 2008-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064031A1 (es) | Compuestos de azaindolilo y metodos de uso | |
| AR062468A1 (es) | Compuestos de azabenzofuranil y metodos de uso | |
| AR062469A1 (es) | Compuestos de azabenzotiofeno y azabenzofurano como inhibidores de la quinasa mek, una composicion farmaceutica que los comprende y el uso de estos en el tratamiento de trastornos inflamatorios e hiperproliferativos. | |
| AR069803A1 (es) | 5- anilinoimiazopiridinas y metodos de uso | |
| RU2011103454A (ru) | Бициклические гетероциклы в качестве ингибиторов киназы мек | |
| RU2011103434A (ru) | Изоиндолоны и способы их применения | |
| AR060054A1 (es) | Inhibidores de c-met protein quinasas. composiciones farmaceuticas. | |
| ES2595031T3 (es) | Composiciones y métodos para la detección de aberraciones cromosómicas con tampones de hibridación novedosos | |
| CY1124357T1 (el) | Προσδιορισμος ανισορροπιας αλληλουχιας νουκλεϊκων οξεων | |
| AR058542A1 (es) | Compuestos herbicidas derivados de isoxazolina, procesos de preparacon, composiciones que los comprenden y uso en el control o inhibicion de plantas. | |
| PE20071022A1 (es) | Compuestos derivados de dibencilamina como inhibidores de la proteina de transferencia del colesteril ester (cept) | |
| AR050793A1 (es) | Derivados de isoxazolina, procedimientos para su preparacion y su uso como herbicidas | |
| BR112018016671A2 (pt) | sulfonilureias e compostos relacionados e uso do mesmo | |
| AR075022A1 (es) | Derivados oxadiazole como agonistas de los receptores de esfingosina-1-fosfato (s1p1) | |
| PE20080409A1 (es) | Compuestos que modulan en el receptor cb2 | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| PE20091952A1 (es) | Compuestos de tiazole y oxazole de sulfonamida de benzeno | |
| PE20120635A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| AR054814A1 (es) | Derivados de piridazina | |
| PE20120229A1 (es) | Compuestos heterociclicos como inhibidores de proteasa aspartica | |
| PE20120031A1 (es) | Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1 | |
| PE20070768A1 (es) | Derivados de fenil-1,2,4-oxadiazolona con grupo fenilo, procedimientos para su preparacion | |
| PE20130008A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
| CY1115302T1 (el) | Ενωση οξαζολιου και φαρμακευτικη συνθεση | |
| PE20130647A1 (es) | Indoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |